Vaccine Adjuvants Market is projected to grow from USD 1.5 billion in 2022 to USD 1.6 billion by 2027, at a CAGR of 1.7% from 2022 to 2027, according to a new report by MarketsandMarkets™. 

Vaccine adjuvants are ingredients that are added to vaccines to help boost their immune-stimulating effects. As the demand for vaccines and other immunological treatments continues to grow, the global vaccine adjuvants market is poised to experience significant growth over the next few years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

The introduction of new vaccines has created an increased demand for vaccine adjuvants. These adjuvants are used to improve the effectiveness of vaccines, reduce their side effects, and extend their protection against disease. Vaccine adjuvants can be broadly categorized into two types: oil-in-water adjuvants and water-in-oil adjuvants.

The global vaccine adjuvants market is driven by the increasing prevalence of infectious diseases, growing awareness about the importance of immunization, and the rising availability of advanced vaccine adjuvants. Additionally, the increasing demand for combination vaccines and the emergence of new vaccine adjuvants are likely to fuel the growth of this market in the coming years.

Moreover, the rising investment in research and development activities to develop new and improved adjuvants, as well as the availability of advanced vaccine delivery systems, are expected to spur the growth of the vaccine adjuvants market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market in 2021.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets of the region is drive by increasing investments in the life sciences sector and rising awareness through conferences & symposiums, and growing emphasis on strategic initiatives such as partnerships, and collaborations by biopharma and biotech companies.

Key Market Players

Key players in the vaccine adjuvants market include GSK plc (UK), Dynavax Technologies (US), Novavax (US), Agenus Inc. (US), Croda International plc (UK), Seppic (France), OZ Biosciences (US), Phibro Animal Health Corporation (US), Associated British Foods plc (UK), InvivoGen (US), Merck KGaA (Germany), CSL Limited (Australia), Vertellus (US), Allergy Therapeutics (UK), Riboxx GmbH (Germany), CaPtivatϵ Pharmaceuticals LLC (US), EuBiologics Co., Ltd. (South Korea), Pacific GeneTech Limited (US), Hawaii Biotech Inc. (US), and Vaxine Pty Ltd. (Australia).

GSK plc (UK)

GlaxoSmithKline (UK) held the leading position in the market in 2021. The company has entered into collaborations and partnerships with a number of vaccine developers and is recognized for its contrition in the COVID-19 space. SK Bioscience (South Korea), Bharat Biotech International Limited (India), and Government of Canada (Canada) are some of the major partners of the company.

Dynavax Technologies (US)

In 2021, Dynavax focuses on inorganic growth strategies to maintain its market position. Biological E Limited (India), Clover Biopharmaceuticals (China), Valneva SE (France), and Medigen Vaccine Biologics (China) are some of the company’s partners in vaccine development.

Novavax (US)

Novavax is also one of the leading players in the vaccine adjuvants market. The company focuses on inorganic growth strategies such as partnerships to strengthen its market position. The company partnered with AGC Biologics (Denmark) and Serum Institute of India (India) for the development of vaccines for COVID-19 and malaria.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894